Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | NOS2 | P35228 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | CTRC | Q99895 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402909 | 0.90 | FAAH (0.40) | NOS1NOS2PRSS1CTRCF2 | |
| SCHEMBL3535755 | 0.86 | NOS1 (0.40) | NOS1NOS2PRSS1CTRCF2 | |
| SCHEMBL22273296 | 0.82 | NOS1 (0.35) | NOS1NOS2PRSS1CTRCF2 | |
| SCHEMBL17964264 | 0.81 | TP53 (0.50) | NOS1NOS2PRSS1CTRCF2 | |
| SCHEMBL22264485 | 0.80 | TP53 (0.36) | NOS1NOS2PRSS1CTRCF2 | |
| SCHEMBL28168174 | 0.79 | PRSS1 (0.34) | NOS1NOS2PRSS1CTRCF2 | |
| SCHEMBL29886436 | 0.77 | — | — | |
| SCHEMBL15423555 | 0.77 | — | — | |
| SCHEMBL2051321 | 0.77 | — | — | |
| SCHEMBL3942028 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5114701-A | Oxidation and reduction of an anthraquinone in carbamate | KEMIRA OY (FI) | 1992-05-19 | — | — | US | claimed |
| EP-2167621-B1 | ORGANIC COMPOUNDS AS ODORANTS | GIVAUDAN SA (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-9012391-B2 | Organic compounds | GIVAUDAN SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20100292128-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-2167621-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008151455-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-12-18 | — | — | WO | disclosed |
| EP-0611126-B1 | A hydrogenation catalyst for use in a hydrogen peroxide process, and a method for the preparation thereof | KEMIRA OY (FI) | 1998-11-25 | — | — | EP | disclosed |
| US-5435985-A | Anthraquinone process using metal catalysts of palladium group or platinum group with other metals | KEMIRA OY (FI) | 1995-07-25 | — | — | US | disclosed |
| EP-0611126-A1 | A hydrogenation catalyst for use in a hydrogen peroxide process, and a method for the preparation thereof | KEMIRA OY (FI) | 1994-08-17 | — | — | EP | disclosed |
| US-5114701-A | Oxidation and reduction of an anthraquinone in carbamate | KEMIRA OY (FI) | 1992-05-19 | — | — | US | disclosed |
| EP-0095822-B1 | HYDROGEN PEROXIDE PROCESS | FMC Corporation (US) | 1985-06-12 | — | — | EP | disclosed |
| US-4457944-A | REFATTING OILS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1984-07-03 | — | — | US | disclosed |
| EP-0095822-A1 | Hydrogen peroxide process | FMC Corporation (US) | 1983-12-07 | — | — | EP | disclosed |
| US-4394369-A | AUTOOXIDATION OF ANTHRAQUINONE IN A N-SUBSTITUTED PYRROLIDONE SOLVENT | FMC CORPORATION (US) | 1983-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292128-A1 | Organic Compounds | TRPA1, FASN, OR10J3 | NOS1 2330/4885NOS2 2178/4885PRSS1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.